157 related articles for article (PubMed ID: 7588455)
1. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial.
Cramer J; Vachon L; Desforges C; Sussman NM
Epilepsia; 1995 Nov; 36(11):1111-7. PubMed ID: 7588455
[TBL] [Abstract][Full Text] [Related]
2. Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures.
Petroff OA; Hyder F; Collins T; Mattson RH; Rothman DL
Epilepsia; 1999 Jul; 40(7):958-64. PubMed ID: 10403220
[TBL] [Abstract][Full Text] [Related]
3. Gamma-vinyl GABA (vigabatrin) and mood disturbances.
Aldenkamp AP; Vermeulen J; Mulder OG; Overweg J; Van Parys JA; Beun AM; Van 't Slot B
Epilepsia; 1994; 35(5):999-1004. PubMed ID: 7925172
[TBL] [Abstract][Full Text] [Related]
4. Dose-Response Study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures.
Dean C; Mosier M; Penry K
Epilepsia; 1999 Jan; 40(1):74-82. PubMed ID: 9924905
[TBL] [Abstract][Full Text] [Related]
5. Vigabatrin serum concentration to dosage ratio: influence of age and associated antiepileptic drugs.
Armijo JA; Cuadrado A; Bravo J; Arteaga R
Ther Drug Monit; 1997 Oct; 19(5):491-8. PubMed ID: 9357089
[TBL] [Abstract][Full Text] [Related]
6. The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism.
Spanaki MV; Siegel H; Kopylev L; Fazilat S; Dean A; Liow K; Ben-Menachem E; Gaillard WD; Theodore WH
Neurology; 1999 Oct; 53(7):1518-22. PubMed ID: 10534261
[TBL] [Abstract][Full Text] [Related]
7. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study.
Tanganelli P; Regesta G
Epilepsy Res; 1996 Nov; 25(3):257-62. PubMed ID: 8956924
[TBL] [Abstract][Full Text] [Related]
8. Visual field loss associated with vigabatrin: quantification and relation to dosage.
Hardus P; Verduin WM; Engelsman M; Edelbroek PM; Segers JP; Berendschot TT; Stilma JS
Epilepsia; 2001 Feb; 42(2):262-7. PubMed ID: 11240600
[TBL] [Abstract][Full Text] [Related]
9. Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study.
Feucht M; Brantner-Inthaler S
Epilepsia; 1994; 35(5):993-8. PubMed ID: 7925171
[TBL] [Abstract][Full Text] [Related]
10. Once-daily versus twice-daily vigabatrin: is there a difference? The results of a double-blind pilot study.
Zahner B; Stefan H; Blankenhorn V; Krämer G; Richens A; Thümler R; Mumford JP
Epilepsia; 1999 Mar; 40(3):311-5. PubMed ID: 10080511
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?
McKee PJ; Blacklaw J; Friel E; Thompson GG; Gillham RA; Brodie MJ
Epilepsia; 1993; 34(5):937-43. PubMed ID: 8404750
[TBL] [Abstract][Full Text] [Related]
12. Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. French Neurologists Sabril Study Group.
Arzimanoglou AA; Dumas C; Ghirardi L
Seizure; 1997 Jun; 6(3):225-31. PubMed ID: 9203252
[TBL] [Abstract][Full Text] [Related]
13. Vigabatrin: 2008 update.
Willmore LJ; Abelson MB; Ben-Menachem E; Pellock JM; Shields WD
Epilepsia; 2009 Feb; 50(2):163-73. PubMed ID: 19230067
[TBL] [Abstract][Full Text] [Related]
14. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy.
Dodrill CB; Arnett JL; Sommerville KW; Sussman NM
Epilepsia; 1995 Feb; 36(2):164-73. PubMed ID: 7821274
[TBL] [Abstract][Full Text] [Related]
15. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures.
Hosford DA; Wang Y
Epilepsia; 1997 Apr; 38(4):408-14. PubMed ID: 9118845
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study.
Dalla Bernardina B; Fontana E; Vigevano F; Fusco L; Torelli D; Galeone D; Buti D; Cianchetti C; Gnanasakthy A; Iudice A
Epilepsia; 1995 Jul; 36(7):687-91. PubMed ID: 7555986
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin-8 sulfate modulates the anticonvulsant efficacy of vigabatrin in an experimental model of partial complex epilepsy in the rat.
Ferraro G; Sardo P
Epilepsia; 2009 Apr; 50(4):721-30. PubMed ID: 19220409
[TBL] [Abstract][Full Text] [Related]
18. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group.
Mauguière F; Chauvel P; Dewailly J; Dousse N
Epilepsia; 1997 Mar; 38(3):301-8. PubMed ID: 9070592
[TBL] [Abstract][Full Text] [Related]
19. Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms.
Granström ML; Gaily E; Liukkonen E
Epilepsia; 1999 Jul; 40(7):950-7. PubMed ID: 10403219
[TBL] [Abstract][Full Text] [Related]
20. [Vigabatrin: results with a new antiepileptic agents in 57 patients in a general neurological practice].
van der Zwan A; van der Zwan A
Ned Tijdschr Geneeskd; 1994 Sep; 138(37):1859-63. PubMed ID: 7935922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
